Rapid 30-minute isatuximab infusions improve patient experiences and reduce healthcare system burdens without compromising safety. FDA-approved isatuximab with VRd shows a 40% risk reduction in ...

Effect of armed oncolytic adenovirus on immunotherapy for primary and metastatic brain tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...

Subcutaneous amivantamab offers a convenient alternative to IV administration for EGFR-mutated NSCLC, reducing infusion-related reactions and administration time. The PALOMA-3 trial confirmed ...